Drug intelligence / Profile preview

SYH2082

Development stage: Phase 1
Lead developer: CSPC Pharmaceutical Group
Modality: Peptides
Administration: Subcutaneous

Overview

SYH2082 is a long-acting dual agonist of the glucagon-like peptide-1 receptor (GLP-1R) and the glucose-dependent insulinotropic polypeptide receptor (GIPR). Originally developed by CSPC Pharmaceuticals, the drug was licensed to AstraZeneca in 2024 for global development and commercialization outside of China. SYH2082 is intended for weight management and the treatment of obesity, utilizing the synergistic effects of dual incretin receptor activation to regulate appetite, improve glycemic control, and enhance metabolic health. It is currently in Phase 1 clinical development.

Targets

GIPR (Gastric inhibitory polypeptide receptor)GLP1R (GLP-1R)

Beyond the preview

Go deeper on SYH2082.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SYH2082.

Explore the full profile